Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency

Abstract The abnormal accumulation of amyloid fibrils in the brain is pathognomonic of Alzheimer's disease. Amyloid fibrils induce significant neuroinflammation characterized by the activation of microglia and impairment of synaptic plasticity in the brain that eventually leads to cognitive dec...

Full description

Saved in:
Bibliographic Details
Published inNeurobiology of aging Vol. 34; no. 12; pp. 2843 - 2852
Main Authors Wu, Jiang, Bie, Bihua, Yang, Hui, Xu, Jijun J, Brown, David L, Naguib, Mohamed
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract The abnormal accumulation of amyloid fibrils in the brain is pathognomonic of Alzheimer's disease. Amyloid fibrils induce significant neuroinflammation characterized by the activation of microglia and impairment of synaptic plasticity in the brain that eventually leads to cognitive decline. Chemokine fractalkine receptor (CX3CR1) is primarily located in the microglia in the brain and its role in the amyloid fibril-induced neuroinflammation and memory deficiency remains debated. We found that bilateral microinjection of amyloid beta (Aβ)1–40 fibrils into the hippocampal CA1 area of rats resulted in significant upregulation of CX3CR1 messenger RNA (mRNA) and protein expression (via increasing histone H3 acetylation in the Cx3cr1 promoter region), synaptic dysfunction, and cognitive impairment, compared with the control group. Suppressing CX3CR1 signaling with CX3CR1 small interfering RNA in rats injected with Aβ1–40 fibrils blunted Aβ1–40 -induced CX3CR1 upregulation, microglial activation, interleukin-1β expression, restored basal glutamatergic strength and electric stimuli-induced long-term potentiation, and cognitive capacities. These findings suggest that activation of CX3CR1 plays an important role in the neuroinflammatory response and Aβ-induced neuroinflammation and neurotoxicity.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2013.06.003